Iovance Biotherapeutics shares are trading higher after the FDA accepted the company's Biologics License Application for lifileucel.
Portfolio Pulse from Benzinga Newsdesk
Iovance Biotherapeutics' shares are trading higher after the FDA accepted the company's Biologics License Application for lifileucel.
May 30, 2023 | 12:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Iovance Biotherapeutics' stock price is likely to increase in the short term due to the FDA's acceptance of the Biologics License Application for lifileucel.
The FDA's acceptance of Iovance Biotherapeutics' Biologics License Application for lifileucel is a positive development for the company. This regulatory milestone is likely to boost investor confidence in the company's product pipeline and lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100